230
Participants
Start Date
January 31, 2002
Primary Completion Date
December 31, 2005
Study Completion Date
September 30, 2008
Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab
"Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d~Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d"
Ludwig Maximillian University Munich, Department of Gynecology and Obstetrics, Munich
AGO Study Group
OTHER
GBG Forschungs GmbH
OTHER